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Background: Hypofractionated stereotactic body radiation therapy (SBRT) has been advanced as monotherapy for
low-risk prostate cancer. We examined the dose distributions and early clinical outcomes using this modality for the
treatment of intermediate-risk prostate cancer.
Methods: Forty-one sequential hormone-naïve intermediate-risk prostate cancer patients received 35–36.25 Gy of
CyberKnife-delivered SBRT in 5 fractions. Radiation dose distributions were analyzed for coverage of potential
microscopic ECE by measuring the distance from the prostatic capsule to the 33 Gy isodose line. PSA levels,
toxicities, and quality of life (QOL) measures were assessed at baseline and follow-up.
Results: All patients completed treatment with a mean coverage by the 33 Gy isodose line extending >5 mm
beyond the prostatic capsule in all directions except posteriorly. Clinical responses were documented by a mean
PSA decrease from 7.67 ng/mL pretreatment to 0.64 ng/mL at the median follow-up of 21 months. Forty patients
remain free from biochemical progression. No Grade 3 or 4 toxicities were observed. Mean EPIC urinary irritation/
obstruction and bowel QOL scores exhibited a transient decline post-treatment with a subsequent return to
baseline. No significant change in sexual QOL was observed.
Conclusions: In this intermediate-risk patient population, an adequate radiation dose was delivered to areas of
expected microscopic ECE in the majority of patients. Although prospective studies are needed to confirm
long-term tumor control and toxicity, the short-term PSA response, biochemical relapse-free survival rate, and QOL
in this interim analysis are comparable to results reported for prostate brachytherapy or external beam radiotherapy.
Trial registration: The Georgetown Institutional Review Board has approved this retrospective study (IRB 2009–510).
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HypofractionationBackground
The treatment of prostate cancer has evolved to include
optimization of radiation dose distributions and radiobi-
ological effectiveness. Clinical evidence suggests that the
α/β ratio of prostate cancer is perhaps as low as 1.5-2
Gy [1]. Given an α/β ratio for prostate cancer that is less
than the generally accepted value of 3 Gy for late rectal* Correspondence: SPC9@gunet.georgetown.edu
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reproduction in any medium, provided the orcomplications, the linear-quadratic model predicts a
greater therapeutic gain for hypofractionated courses of
radiotherapy over conventionally fractionated treatment
regimens. Early experience with investigations of limited
hypofractionation (fraction sizes from 2.5 to 3.5 Gy) has
revealed that such regimens are effective without undue
toxicity [2]. One Phase III trial has shown comparable
toxicities and improved freedom from biochemical fail-
ure with a hypofractionated treatment regimen of 62 Gy
in 20 fractions compared to a conventionally fractio-
nated regimen of 80 Gy in 40 fractions [3]. The linear-This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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may provide additional improvements in control.
Large radiation fractions have been successfully used
as a boost to escalate the dose to the prostate and se-
minal vesicles (SV). The hypofractionated boost is used
to supplement a course of conventionally fractionated
external-beam radiotherapy (EBRT) designed to treat a
larger volume encompassing the microscopic disease ad-
jacent to the prostate and seminal vesicles. Studies inves-
tigating a high dose-rate (HDR) brachytherapy boost
delivering 4–11.5 Gy/fraction over 2 to 4 sessions com-
bined with EBRT report five-year biochemical control
rates in excess of 85% for intermediate-risk prostate
cancer patients with acceptable toxicities [4]. The tight
margins and steep dose gradients delivered with HDR
brachytherapy can be approximated with SBRT using
the CyberKnife (CK) system, [5,6] which uses real-time
image guidance to account for intrafraction prostatic
motion [7]. EBRT with an SBRT boost has been explored
in intermediate-risk prostate cancer with favorable early
results [8,9].
Delivering an entire course of radiotherapy for pros-
tate cancer using large fractions rather than as a boost
to a course of conventionally fractionated EBRT could
be radiobiologically advantageous. The safety, efficacy,
and convenience of such monotherapy with hypofractio-
nated courses of treatment at 6–9.5 Gy per fraction has
been demonstrated for localized prostate cancer using
HDR brachytherapy [10-15]. Initial published outcomes
for hypofractionated SBRT using the CK system as mo-
notherapy for patients with clinically localized prostate
cancer show PSA responses and toxicity profiles that are
historically comparable to conventional external beam
radiotherapy or HDR brachytherapy [16-24]. However,
with the exception of the recent paper by Lee et al., the
majority of the patients in these studies have low-risk
disease, and there is a concern that the tight margins
required to limit the normal tissue doses to the rectum
and bladder in hypofractionated radiotherapy may not
be adequate to treat the microscopic disease from extra-
capsular extension (ECE) and SV involvement that is
present in 35–50% of intermediate-risk patients [25].
Here, we provide dosimetric data to support the ad-
equacy of such treatment and report the early outcomes
for intermediate-risk prostate cancer patients treated
with hypofractionated SBRT monotherapy using the CK
system.
Methods
This retrospective review of prospectively collected data
from 41 consecutively treated patients receiving hypo-
fractionated stereotactic body radiotherapy at Georgetown
University Hospital as monotherapy for histologically-con-
firmed intermediate-risk prostate cancer. Intermediaterisk was defined using the National Comprehensive Can-
cer Network (NCCN) criteria of patients with at least one
of the following risk factors: Stage T2b - T2c disease, a
Gleason score of 7, or a PSA of 10 – 20 ng/mL [26]. Clin-
ical stage was assigned according to the 6th edition of the
American Joint Committee on Cancer definitions. Ex-
clusion criteria included less than one year of clinical fol-
low-up, clinical involvement of lymph nodes or distant
metastases on pre-treatment imaging, prior prostate can-
cer-directed therapy, or prior pelvic irradiation. Patients
who received androgen deprivation therapy (ADT) were
excluded. Institutional review board approval was obtai-
ned for this analysis.
Treatment planning and delivery
The fiducial placement and CT/MRI simulation proce-
dures have been previously described in Lei et al. [27]
The gross tumor volume (GTV) was defined as the
prostatic capsule and the proximal seminal vesicles up
to the point that the left and right seminal vesicles sepa-
rated. To create the clinical target volume (CTV), this
volume was further expanded 3 mm posteriorly and 5
mm in all other directions to cover areas of potential
ECE. The planning target volume (PTV) was equal to
the CTV. No attempt was made to spare the neurovas-
cular bundles in treatment planning. Treatment plan-
ning was performed using Multiplan (Accuray Inc.,
Sunnyvale, CA). The prescription dose was either 35 or
36.25 Gy to the PTV in 5 fractions over 1–2 weeks.
Patients with an elevated pre-treatment AUA scores,
large prostates, or medical co-morbidities were pres-
cribed the lower dose [20]. The target doses and dose
constraints have been described in Oermann et al. [28]
During treatment, paired orthogonal x-rays were taken
every 3–6 beams to adjust for the translational and rota-
tional intrafraction movement of the prostate, with the
goal of keeping the translational corrections between
images to less than 2 mm, and the rotational corrections
to less than 5 degrees. This corresponds to approxima-
tely every 30–60 seconds at the start of treatment, and
the time between images is varied during the course
of treatment depending on amount of prostate motion
[7,27]. All plans were reviewed and approved by a single
experienced physician in our institution (S.C.). Figure 1
shows an axial view of a typical treatment plan. Quality
assurance for the SBRT plans was assured by a weekly
departmental review of cases.
Pretreatment assessment and follow-up
A clinical examination including a digital rectal exam
(DRE), a PSA level, and a quality of life (QOL) question-
naire were performed prior to the initiation of stereotac-
tic body radiotherapy, at 1 and 3 months post-treatment,
and every 3 months thereafter. The QOL questionnaires
Figure 1 Example treatment plan showing an axial view. The volumes represent the GTV (red), PTV (blue) and rectum (light green). The
prescription isodose line (79%) is denoted by the thick light blue line.
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the International Prostate Symptom Score (IPSS), [29]
the Expanded Prostate Cancer Index Composite (EPIC)
short form, [30] and the 12-item Medical Outcomes
Study Short Form (SF-12) version 2 questionnaires [31].
Acute and late toxicities were scored using the Common
Terminology Criteria for Adverse Events (CTCAE) Ver-
sion 4.0. Acute toxicity is defined as occurring within 6
months of completing treatment, and late toxicity as
those events occurring later than 6 months. Biochemical
failure was defined as a PSA rise of ≥ 2 ng/mL above the
nadir [32].Dosimetric assessment
The coverage of potential extracapsular extension of dis-
ease with a dose sufficient to control gross and micro-
scopic disease was the focus of evaluation. The distance
from the GTV to the 33 Gy isodose line of the treatment
plans was measured in 45 degree increments on 3 axial
planes: the plane 1 cm caudal from the base of the pros-
tate, the plane 0.5 cm cranial from the apex, and the
plane in the mid-prostate halfway between the 2 other
planes. This dosimetric analysis has been previously
described in brachytherapy implants [33,34]. The 33 Gy
isodose line was chosen as the dose that would treat po-
tential ECE. Conservatively assuming an α/β ratio of 3
Gy, the linear-quadratic equation would predict that this
corresponds to a dose of 66 Gy delivered in 1.8 Gy daily
fractions, which is the dose considered sufficient for
treating microscopic residual disease in the prostatic
fossa after prostatectomy [35]. In our SBRT study 33 Gy
is greater than 90% of the prescription dose.Statistical analysis
Descriptive statistics were used to summarize the pa-
tients’ baseline clinical characteristics, the dosimetric cha-
racteristics, as well as the rates of observed toxicities.
QOL data from time points in which more than 80% of
patients completed the questionnaires were included in
the analysis. An QOL change of one-half standard devi-
ation (SD) from the baseline QOL score, defined as the
minimal important difference (MID), was used to denote
a clinically significant change in the QOL score [36]. The
two-sided paired Wilcoxon rank-sum test was used to cal-
culate the significance of differences in the mean scores
on follow-up as compared to the baseline values. Pa-
rameters were identified as significant if the two-tailed
p-value was less than 0.05. MedCalcW version 11.6.1.0 was
used for the statistical analyses.
Results
Patients
Forty-one men were treated between October 1, 2008
and October 30, 2009 met the inclusion criteria. Their
baseline characteristics are summarized in Table 1. The
median clinical follow-up is 21 months (range 13 – 27.5
months). Eight patients received a total dose of 35 Gy,
and 33 patients received 36.25 Gy. The median prescrip-
tion isodose line was 77% (range 75%–80%), which cov-
ered a median 95.1% of the PTV (range 94.2%–96.4%).
The dosimetric constraints to normal tissues were met
in the majority of patients.
Dosimetric analysis
The mean 33 Gy isodose line extends beyond 5 mm
from the prostate capsule in the anterior, lateral and
Table 1 Patient characteristics






Prostate volume (cc) Median Range
37 20–63
PSA (ng/mL) Median Range
6.9 3.5–18.3














* Factors include PSA 10–20 ng/mL, Gleason 7, or T2b-2c.
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lyzed. The mean and range of these distances are listed
in Table 2, along with the percent of patients who re-
ceive 33 Gy at 3, 4, 5, 6, and 7 mm on the treatment
plan. The mean distances posteriorly from the prostatic
capsule to the rectum are also listed in Table 2. The
mean distances of the 33 Gy isodose line with the 95%
confidence interval of the mean are graphed in a radar
plot in Figure 2. For the majority of patients the cover-
age of the 33 Gy isodose line is more than 5 mm in the
directions where ECE is a greater concern including the
posteriolateral directions, while the extension of the high
dose region into the rectum is short in comparison.
Biochemical response
PSA values declined from a baseline mean of 7.67 ng/
mL (SD 3.26 ng/mL) to a mean of 1.35 ng/mL (SD 1.08
ng/mL) at 12 months, and 0.64 ng/mL (SD 0.40 ng/mL)
at 21 months. There have been no deaths from any cause
to date. The 2-year Kaplan-Meier biochemical relapse-free
survival rate is 97.6%. One patient experienced a biochem-
ical failure 15 months after treatment. This patient had a
prior history of obstructive urinary symptoms treated withtransurethral microwave therapy prior to initiating radio-
therapy. He had a baseline PSA of 6.9 ng/mL which
decreased to a nadir of 2.0 ng/mL at 9 months, and then
rose to 3.9 and 4.2 ng/mL in the next 2 follow-up visits
while he was experiencing worsening urinary obstructive
symptoms, before decreasing again to 2.1 ng/mL on sub-
sequent follow-up. The patient was never started on ADT.
Given the possibility that his rise in PSA was a benign
bounce’ due to his urinary symptoms, [37] the patient is
not considered to have clinically failed treatment and is
currently under observation.
Toxicity and quality of life
As previously reported, low grade urinary and rectal
toxicities were common following prostate SBRT [28].
The most common urinary toxicities were frequency and
urinary obstructive symptoms. The course of symptoms
peaked 1–2 weeks following completion of SBRT, fol-
lowed by an improvement within 2–3 months. Forty-
four percent of patients experienced a late Grade 2 urin-
ary toxicity. These correlated with alpha receptor antag-
onist utilization for low grade symptoms. The most
common bowel toxicity was frequency of bowel move-
ments. Seven percent of patients experienced Grade 2
late bowel toxicity secondary to rectal bleeding due to
exacerbation of hemorrhoids that required ligation, ban-
ding, or laser coagulation. There were no Grade 3 or
higher acute or late toxicities.
Figure 3 summarizes the baseline and follow-up urin-
ary, bowel, and sexual QOL scores. Eighty percent of
patients completed their QOL questionnaires for at least
15 months. The mean IPSS (Figure 3a) and the mean
EPIC urinary irritation/obstructive scores (Figure 3b) sho-
wed clinically significant (score decreased by >1/2 SD)
and statistically significant (p<0.001 and p=0.035, respec-
tively) transient decrements one month post-treatment
that subsequently returned to baseline. The mean EPIC
urinary incontinence score (Figure 3c) was statistically
worse at 1 month (p=0.005), but improved by 3 months.
Additional decline was observed at 9 months, but this has
not reached clinical or statistical significance. The EPIC
bowel score (Figure 3d) showed a clinically and statis-
tically significant (p<0.001) decline at 1 month post-
treatment with recovery at 15 months post-treatment.
EPIC sexual scores (Figure 3e) showed a slow decline
over the first year following treatment; however, the
decline was not clinically or statistically significant. No
clinically or statistically significant decrease occurred in
the SF-12 physical or mental component QOL scores
(data not shown).
Discussion
Although IMRT is the standard external beam modality
for clinically localized prostate cancer, hypofractionated
Table 2 Coverage of potential ECE
Axial plane 1 cm















Anterior 7.82 1.10 – 14.42 95% 88% 85% 73% 61%
Left 8.59 4.47 – 18.46 100% 100% 95% 85% 73%
Right 8.41 4.62 – 18.15 100% 100% 95% 71% 59%
Left posterolateral 11.42 3.11 – 27.02 100% 98% 88% 83% 76%
Right posterolateral 11.03 3.12 – 27.02 100% 98% 88% 80% 73%
Posterior 1.92 −0.66 – 6.070 20% 7% 5% 2% 0%
Distance from rectum
to prostate capsule

















Anterior 9.01 4.42 – 17.32 100% 100% 98% 76% 68%
Left 8.48 4.47 – 16.12 100% 100% 98% 88% 66%
Right 7.57 3.53 – 15.20 100% 98% 90% 76% 49%
Left posterolateral 7.87 2.04 – 26.86 98% 95% 83% 61% 51%
Right posterolateral 7.60 0 – 20.10 95% 85% 78% 68% 51%
Posterior 1.97 −0.66 – 4.86 29% 12% 0% 0% 0%
Distance from rectum
to prostate capsule
0.87 0 – 3.58
















Anterior 9.53 3.56 – 15.38 100% 95% 95% 95% 83%
Left 13.40 7.64 – 22.09 100% 100% 100% 100% 100%
Right 12.28 5.55 – 21.36 100% 100% 100% 98% 95%
Left posterolateral 7.25 0 – 17.34 93% 85% 73% 61% 44%
Right posterolateral 7.27 0 – 15.81 98% 93% 85% 68% 51%
Posterior 2.86 0 – 6.83 41% 24% 12% 2% 0%
Distance from rectum
to prostate capsule
0.79 0 – 3.50
Mean distance (mm) with range between the prostatic capsule and the 33 Gy isodose line, with the percent of patients where the distance is greater than or equal to 3, 4, 5, 6, and 7 mm. The mean distance between
















Figure 2 Coverage of potential ECE. Radar plots of the mean distance (solid red line) in millimeters of the 33 Gy isodose line from an idealized
prostate GTV (solid black line). The 95% confidence interval of the mean is shown in dashed blue lines. The distances are shown on (a) the axial
plane 1 cm caudal to base, (b) the axial plane in mid-prostate, and (c) the axial plane 0.5 cm cranial to apex.
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tial alternative [18]. The studies that have the longest
follow-up use the CyberKnife machine for SBRT de-
livery, but prostate SBRT can also be delivered using
other systems that account for intrafraction motion,
such as the electromagnetic Calypso system or a transperi-
neal ultrasound system. Multiple single institution experi-
ences with SBRT monotherapy in favorable risk patients
use a regimen of 35–40 Gy is delivered to the prostate in
4–5 fractions. Their results suggest that this approachmay provide similar clinical outcomes to IMRT, and re-
port high biochemical control rates with acceptable tox-
icity [5,16-24]. Recent updates have confirmed a 5-year
biochemical disease-free survival in low-risk patients is in
excess of 90% [17,21].
These SBRT monotherapy studies include mostly low-
risk patients, and there is limited data on the use of hy-
pofractionated radiotherapy in intermediate-risk patients,
where ECE is more common and the treatment margins
may not adequately cover this extraprostatic disease.
Figure 3 (a-e) Mean quality of life measures at baseline and follow-up. Analysis of the QOL data included all time points that had at least
an 80% patient response rate, which was up to 15 months for all QOL measures. Shown are plots for IPSS (a), EPIC urinary irritation/obstruction
domain (b), EPIC urinary incontinence domain (c), EPIC bowel domain (d), and EPIC sexual domain (e). The thresholds for clinically significant
changes in scores (½ standard deviation above and below the baseline) are marked with dashed lines. IPSS scores range from 0–35 with higher
values representing worsening urinary symptoms. EPIC scores range from 0–100 with higher values representing a more favorable
health-related QOL.
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that the extent of microscopic ECE in intermediate-risk
patients is generally small (2–3 mm) and a 4 to 5 mm mar-
gin around the prostatic capsule should cover this spread of
disease in an estimated 90-99% of intermediate-risk patients
[25,33,38-41]. We consider 33 Gy (94% of the prescription
dose for 35 Gy plans or 91% of the 36.25 Gy plans) to be an
adequate dose for treating microscopic disease. In our study,
the mean distance of the 33 Gy isodose line on the treat-
ment plans extends >5 mm beyond the prostate capsule in
all directions except directly posteriorly into the rectum,
with generous coverage in the posterolateral directions
where ECE more commonly occurs.
The actual dose delivered to the surrounding margin of
the prostate can be less than the planned dose due to intra-
fraction motion of the prostate. Xie et al. calculated that or-
thogonal imaging every 30–60 seconds would allow 95.6%
and 92.5% of the beams to be delivered within 2 mm of the
target during CyberKnife treatments of the prostate [7].
After taking this 1–2 mm of uncertainty into account, the
ECE coverage with CyberKnife SBRT is comparable to
the coverage achieved in low-dose rate prostate brachy-
therapy. The average distance from the prostatic capsule
of the 33 Gy isodose line in our study in the posteriolateral
direction was 11.23 mm at the base, 7.74 mm at the mid-prostate, and 7.26 mm at the apex. This is comparable to
the Merrick et al. study, where the distances from the
prostate to the 90% isodose line in their series of Pd-103
implants as 8.4 mm at the base, 5.9 mm at the mid-pros-
tate, and 6.8 mm at the apex [34]. The coverage directly
posteriorly towards the rectum is less than in other direc-
tions, but the extent of ECE is smallest in this direction,
where the rectoprostatic fascia limits the extent of inva-
sion [40].
The mean pre-treatment PSA was 7.67 ng/mL and it
decreased to a mean of 1.35 ng/mL by one year post-treat-
ment. PSA data from patients treated with conventional ex-
ternal beam radiation therapy suggest that patients with
PSA nadirs < 2 ng/ml at one year following treatment have
a high rate of long-term disease control, [42,43] and we
could predict a similarly high rate of long-term control in
the patients treated in our series. Given that the majority of
biochemical failures for intermediate-risk patients occur sev-
eral years after treatment, the median follow-up of 21.5
months in the current study is inadequate to establish the
long-term efficacy of CK monotherapy in intermediate-risk
patients. However, our 97.6% 2-year biochemical failure-free
survival rate is consistent with the limited literature on
hypofractionated radiotherapy for intermediate-risk disease.
For HDR monotherapy, which the dose distribution of
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the biochemical control rate specifically for intermediate-
risk patients show excellent 5-year PSA failure-free rates of
93% in Yoshioka et al. and 94% for Rogers et al. [14,15] In
the fractionated SBRT monotherapy literature, only Lee
et al. [24], Bolzicco et al. [16], Katz et al. [20] included a
large percentage of intermediate-risk patients. Lee et al. re-
port their series of 29 patients treated with SBRT to a dose
of 35 to 37.5 Gy in 5 fractions. Nineteen of these patients
had intermediate-risk disease, the others had low or
high risk disease. The 4-year biochemical relapse-free sur-
vival was 86%. There were no Grade 3–4 acute toxicities,
and one patient experienced a late Grade 3 urinary tox-
icity. These results are encouraging, but the results of the
intermediate-risk cohort are not reported independently.
Katz et al. reported a separate biochemical failure rate for
their 81 intermediate-risk patients of 0%, but the follow-
up period of their study was short, with a range of 8 to 37
months for all the patients in the study. Longer follow-up
is needed to validate the observations made in our study
and prospective studies are necessary for comparison to
the reported 70-80% 10-year biochemical failure-free sur-
vivals obtained using conventionally fractionated external
beam radiotherapy and low dose-rate brachytherapy [4].
Our study suggests that clinically significant late Grade
3 toxicities are infrequent following CK monotherapy, and
our low rate is comparable to the rates observed following
external beam radiotherapy,[44] HDR brachytherapy,
[10,11,13,15] or in other reported CK monotherapy series
[8,16,17,21-23]. Our practice allows for prescribing select-
ive alpha blockers for relatively minor urinary complaints,
which may contribute to the higher rate of recorded
Grade 2 late urinary toxicity seen in our series compared
to the rates reported in these other series. However, this
increased higher rate of recorded low grade urinary tox-
icity is not reflected in our QOL results.
The QOL data indicate that CK monotherapy is well tol-
erated, with declines in patient reported urinary, bowel and
sexual function that are similar to those seen in low-risk
patients treated with CK SBRT monotherapy, [28] and com-
parable to the trends seen with conventionally fractionated
external beam radiotherapy and brachytherapy [45-47].
Urinary symptoms peaked in the 1–2 weeks after SBRT, and
were generally followed by improvement to pre-treatment
levels within 2–3 months. Bowel function declined after
treatment and slowly recovered to near baseline at one year.
As reported by others, sexual QOL declined slowly over
time without recovery [47]. Longer follow up is needed to
fully assess the late impact of CyberKnife monotherapy on
QOL.
Conclusions
This analysis assesses the dosimetric feasibility and early
clinical outcomes of hypofractionated stereotactic bodyradiotherapy delivered with the CyberKnife as mono-
therapy for intermediate-risk prostate cancer patients.
On dosimetric evaluation, the treatment plans provide
adequate coverage of potential extracapsular extension
of disease and limits the dose to the adjacent rectum.
Our early results show that the PSA response, absence
of Grade 3 toxicity, and favorable QOL support SBRT
delivered as CyberKnife monotherapy as a safe and poten-
tially effective treatment for intermediate-risk prostate
cancer. Longer follow-up is needed to more accurately as-
sess late toxicities and biochemical failure rates of SBRT
monotherapy in this patient population.
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